CN104127418B - A kind of pharmaceutical composition of cefotiam hydrochloride and application thereof - Google Patents
A kind of pharmaceutical composition of cefotiam hydrochloride and application thereof Download PDFInfo
- Publication number
- CN104127418B CN104127418B CN201410391661.1A CN201410391661A CN104127418B CN 104127418 B CN104127418 B CN 104127418B CN 201410391661 A CN201410391661 A CN 201410391661A CN 104127418 B CN104127418 B CN 104127418B
- Authority
- CN
- China
- Prior art keywords
- cefotiam hydrochloride
- catechin
- pharmaceutical composition
- cefotiam
- ehec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of antibacterial combination, be specifically related to a kind of pharmaceutical composition of cefotiam hydrochloride, more specifically relate to the pharmaceutical composition of a kind of cefotiam hydrochloride and catechin. Active component at least comprises cefotiam hydrochloride and catechin, and 1:0.1～1 is composite in mass ratio, and active component comprises cefotiam hydrochloride and catechin 1:0.5 is composite in mass ratio particularly. This complex composition has synergistic function, can reduce using dosage.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of cefotiam hydrochloride, be specifically related to a kind of cefotiam hydrochloride and catechuThe pharmaceutical composition of element.
Background technology
Cefotiam hydrochloride is second generation cephalosporin, and gram-negative bacteria and positive bacteria are had to antibacterial action widely.Especially to Escherichia coli, Kleb, proteus mirabilis, Bacillus influenzae etc., have shown stronger antibacterial activity. To intestinesRoad Pseudomonas, citrobacter genus, indole-positive proteus vulgaris, Proteus rettgeri, Morganella alsoShown good antibacterial activity, its antibacterial action is bactericidal. Cefotiam hydrochloride can hinder closing of bacteria cell wallBecome. There is stronger antibacterial activity to be because it has good permeability to bacterial cell adventitia and to β-Nei acyl to gram-negative bacteriaAmine enzyme is more stable and high to PBP 1B and 3 compatibilities, thereby has strengthened cell wall mucopeptide cross linkInhibitory action due to.
Catechin is the important component of tealeaves, has the several functions such as prevention and cure of cardiovascular disease, pre-anti-cancer. Dextrorotation catechuEssence reduce in addition capillary permeability, antidiarrheal, hemostasis, antiviral, antifungal, to suppress ACE and preventing gastric ulcer etc. multipleEffect.
Summary of the invention
Technical problem to be solved by this invention is to provide a kind of antibacterial combination.
The present invention addresses the above problem adopted technical scheme: a kind of antibacterial combination, wherein active component1:0.1～1 is composite in mass ratio at least to comprise cefotiam hydrochloride and catechin.
Preferably, a kind of antibacterial combination, wherein active component comprises that cefotiam hydrochloride and catechin are by qualityMore composite than 1:0.2～0.8.
Preferably, a kind of antibacterial combination, wherein active component comprises that cefotiam hydrochloride and catechin are by qualityMore composite than 1:0.4～0.6.
Preferably, a kind of antibacterial combination, wherein active component comprises that cefotiam hydrochloride and catechin are by qualityMore composite than 1:0.5.
Described antibacterial combination, can also add one or more pharmaceutically acceptable auxiliary materials, described accessory packageDraw together diluent, excipient, filler, adhesive, wetting agent, sorbefacient, the surfactant, lubricated of pharmaceutical field routineAgent, stabilizing agent etc., also can add flavouring agent, sweetener and pigment if desired, specifically can be starch, sodium carboxymethyl starch, crystalliteCellulose, lactose, sucrose, polyvinylpyrrolidone, hydroxypropyl cellulose, amylum pregelatinisatum, superfine silica gel powder, dolomol, friendshipOne or more in connection polyvinylpyrrolidone or polyethylene glycol; Described medicine can make comprise tablet, pulvis, granula orOral liquid is at interior oral formulations, or makes parenteral solution.
Another object of the present invention is to provide the composition of cefotiam hydrochloride and catechin in the combination of preparation antibacterialsApplication in thing.
The invention provides cefotiam hydrochloride and catechin use in conjunction is prepared antibacterial compound medicament composition. Experiment cardBright, the independent use of cefotiam hydrochloride can suppress the growth of gram positive bacteria and gram-negative bacteria, but works as cefotiam hydrochlorideWith catechin use in conjunction, the antibacterial efficacy of antibacterials can be obviously strengthened, and the using dosage of antibacterials can be reduced, also canObviously reduce germ attack mouse death rate. Said medicine all can be according to the conventional method preparation of pharmaceutical field.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described in further detail, but embodiments of the present invention are not limited to this.
In following embodiment, method therefor is conventional method if no special instructions.
In experimental example 1, body, detect cefotiam hydrochloride and catechin use in conjunction and gram-negative bacteria is attacked to the guarantor of mouseProtect effect
This experimental study cefotiam hydrochloride and catechin use in conjunction are to gram-negative bacteria (taking EHEC as example)Attack the protective effect of mouse, carry out drug administration by injection mode, specific experiment method is as follows:
180 of mouse, the about 20g of body weight, male and female half and half, are divided into nine groups by injection system at random, 20 every group, are divided into
Control group,
EHEC group,
Catechin (10mg/kg)+EHEC group,
Cefotiam hydrochloride (10mg/kg)+EHEC group,
Catechin (1mg/kg)+cefotiam hydrochloride (9mg/kg)+EHEC group,
Catechin (3.3mg/kg)+cefotiam hydrochloride (6.7mg/kg)+EHEC group,
Catechin (5mg/kg)+cefotiam hydrochloride (5mg/kg)+EHEC group,
Catechin (3mg/kg)+cefotiam hydrochloride (6mg/kg)+EHEC group,
Catechin (2mg/kg)+cefotiam hydrochloride (4mg/kg)+EHEC group.
Wherein: control group gives physiological saline;
EHEC group, gives 10-6The viable bacteria physiological salt liquid of cfu/kg;
Catechin+EHEC group, gives to give 10 after catechin physiological salt liquid again-6Cfu/kg EHEC;
Cefotiam hydrochloride+EHEC group, gives to give 10 after cefotiam hydrochloride physiological salt liquid again-6cfu/kgEHEC;
Catechin+cefotiam hydrochloride+EHEC group, is giving catechin and cefotiam hydrochloride physiological salt liquidAfter give again 10-6Cfu/kg EHEC.
Drug administration by injection is in the normal nursing of mouse, chooses caudal vein, with the wiping repeatedly of 75% cotton ball soaked in alcohol, in order to sterilizationAnd distend the blood vessels, when injection, fixing tail, aims at blood vessel central authorities with left and right, 30 ° of angles inserting needle at tail end 1/3 place, then by pinHead lifts, and as far as possible the angle parallel with afterbody thrust, parallel propelling a little, injection is appropriate to the occasion slowly a small amount of, injects completely, gets cotton ballsPress soft; After administration, observe the situation of 7 days mouse.
Experimental result is as shown in table 1.
Table 1 catechin and cefotiam hydrochloride are combined experimental data (injection) in the body of EHEC
Table 1 experimental result shows that catechin and cefotiam hydrochloride use in conjunction mouse death rate are lower than individually dosed. YoungsterAfter theine and cefotiam hydrochloride drug combination, the mouse of infection due to Escherichia coli is all played to protective effect, can reduce littleThe death rate of mouse. Catechin and cefotiam hydrochloride drug combination produce synergistic function, have greatly reduced the death of mouseRate, and can reduce antibiotic use amount.
As can be seen here, no matter be catechin or cefotiam hydrochloride, the compound of the two formation can reach larger resistingBacterium effect, is better than single preparations of ephedrine separately; And compound its can not bring extra side effect, can not bring in side effect yetDifferent. Show that the compound that catechin and cefotiam hydrochloride form not only has larger antibacterial action, and makeIt is safe using.
Embodiment 2, aseptic powdery injection
Preparation technology:
Wash bottle: the cillin bottle of learning from else's experience and being up to the standards, block pattern row pattern, in stainless steel Revolving disc, goes to wash bottle post. SuccessivelyRinse by purified water, water for injection, blow residual moisture content with compressed air, enter that 350 DEG C of tunnel ovens are dried, sterilizing,Cooling. Go to packing post, by cefotiam hydrochloride (SHANDONG LUOXIN PHARMACY STOCK Co., LTD.) and catechin (the pure aristogenesis in ShanghaiThing Science and Technology Ltd.) mixture be distributed into 1000 bottles.
Wash plug: the chlorinated butyl plug of learning from else's experience and being up to the standards, goes to pour purge tank into after exterior and interior packing 25 points of purified water rinsingsClock, then use water for injection rinsing 25 minutes, enter drying baker and dry, 122 DEG C of sterilizings, 40 minutes time.
Aluminium lid sterilizing: qualified aluminium lid is delivered to baking oven sterilizing, 125 DEG C of sterilising temps, 5 hours time.
Packing, jump a queue: in local 100 grades of clean areas, the vial after sterilizing is sent into racking machine, automatic subpackaging regulationThe aseptic powder of amount, capping plug, proceeds to roll and covers post automatically.
Roll lid: quota is got the aluminium-plastic combined cover through being up to the standards, regulate bottle cap concussion bucket, roll lid. Proceed to lamp inspectionHilllock.
Lamp inspection: lamp inspection under lamp inspection machine, reject defective work, then deliver to label sticking machine by rotating disk.
Packaging: quota is got qualified label, middle box, description, work certificate and large case. By the label of confirmationPressure sensitive adhesive tape installs, and regulates lot number, carries out labeling. Medicine after labeling enters box packing machine by rotating disk. By middle box with sayBright book is placed on the corresponding position of box packing machine, regulates lot number, carries out mounted box. After mounted box, check, case, pack, put in storage.
As mentioned above, just can realize preferably the present invention.
Claims (5)
1. a pharmaceutical composition, is characterized in that: wherein active component is cefotiam hydrochloride and catechin in mass ratio 1:0.5 is composite.
2. the application of pharmaceutical composition claimed in claim 1 in preparation antibacterials.
3. application according to claim 2, is characterized in that: described bacterium is selected from gram positive bacteria or gram-negative bacteria.
4. application according to claim 3, is characterized in that: described gram-negative bacteria is selected from EHEC.
5. pharmaceutical composition according to claim 1, is characterized in that: described pharmaceutical composition is made tablet, pulvis, grainAgent, oral liquid or parenteral solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410391661.1A CN104127418B (en) | 2014-08-11 | 2014-08-11 | A kind of pharmaceutical composition of cefotiam hydrochloride and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410391661.1A CN104127418B (en) | 2014-08-11 | 2014-08-11 | A kind of pharmaceutical composition of cefotiam hydrochloride and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104127418A CN104127418A (en) | 2014-11-05 |
| CN104127418B true CN104127418B (en) | 2016-05-04 |
Family
ID=51800442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410391661.1A Active CN104127418B (en) | 2014-08-11 | 2014-08-11 | A kind of pharmaceutical composition of cefotiam hydrochloride and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104127418B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09132532A (en) * | 1995-09-06 | 1997-05-20 | Mitsui Norin Kk | Enhancement of antimicrobial activity of antibiotic substance |
| WO2007075176A1 (en) * | 2005-12-29 | 2007-07-05 | Mitsui Norin Co., Ltd | Compositions and methods of sensitizing methicillin resistant staphylococcus aureus to oxacillin |
| CN101045733B (en) * | 2007-01-26 | 2011-11-16 | 浙江永宁药业股份有限公司 | Preparation method of cefotiam chloride |
| CN101940574A (en) * | 2010-07-23 | 2011-01-12 | 中国人民解放军第三军医大学 | Application of combination of combined catechin substances with antibacterial drugs |
-
2014
- 2014-08-11 CN CN201410391661.1A patent/CN104127418B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104127418A (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2062582B1 (en) | Antibiotic composition comprising beta-lactam antibiotics, aminoglycosides and buffers | |
| ES2628090T3 (en) | Pharmaceutical compositions and methods to treat or prevent an oxalate-related disease | |
| ES2593727T3 (en) | Caspofungin Composition | |
| JP2009531275A5 (en) | ||
| ES2560527T3 (en) | Stable digestive enzyme compositions | |
| US5599557A (en) | Stable hydrated cephalosporin dry powder for oral suspension formulation | |
| CN105307654A (en) | Compositions and methods for treating microbiota-related psychotropic conditions and diseases | |
| CN103732232A (en) | A composition comprising an antibiotic and a dispersant or an anti -adhesive agent | |
| CN101081301A (en) | Medicinal composition containing pemetrexed | |
| CN101461779A (en) | Disposable ofloxacin eye drops without bacteriostatic agent and preparation method thereof | |
| CN101455633A (en) | Disposable levofloxacin lactate eye drops without bacteria inhibitor and preparation method thereof | |
| CN102895181A (en) | Method for preparing mezlocillin sodium for injection | |
| KR20120004448A (en) | Compositions and methods for elimination of gram-negative bacteria | |
| CN103826639A (en) | Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors | |
| ES2537294T3 (en) | Gemcitabine solution ready to be infused | |
| US20230277497A1 (en) | Enteric aerobization therapy | |
| WO2007081486A2 (en) | Oral administration of defensins to treat intestinal diseases | |
| CN104127418B (en) | A kind of pharmaceutical composition of cefotiam hydrochloride and application thereof | |
| RU2018146395A (en) | DRUGS OF POLYALKYLENE OXIDE-ASPARAGINASE AND METHODS FOR THEIR PRODUCTION AND APPLICATION | |
| CN101522185B (en) | Antidepressant agent | |
| WO2022160531A1 (en) | High-stability daptomycin composition for injection, and preparation method therefor and use thereof | |
| CN103920137A (en) | Pharmaceutical composition having effect of resisting drug-tolerant gram positive bacteria | |
| KR20060124624A (en) | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same | |
| CN101919863A (en) | Cefbuperazone composition | |
| CN103284958B (en) | A kind of Cefdinir composition granule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |